Table A3.
Clinical Characteristics and Overall Survival of the Four Major Categories of SMNs in the Subset of 201 Patients Who Were Not Irradiated and Did Not Undergo Hematopoietic Stem-Cell Transplantation as Part of Their First-Line Treatment for ALL
| Type of Second Cancer | Total |
Males |
ALL Immunophenotype* (n = 192) |
Age at ALL (years) |
WBC at ALL (×109/L) |
Interval to SMN (years) |
Age at SMN (years) |
5-Year Survival Rate After SMN (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | BCP | % | Median | 50% Range | Median | 50% Range | Median | 50% Range | Median | 50% Range | ||
| Total | 201 | 107 | 53.2 | 173 | 90.1 | 3.6 | 2.3-6.6 | 9.0 | 6.5-15.1 | 44.1 ± 3.7 | |||||
| Hematologic† | 145 | 72.1 | 79 | 54.5 | 130 | 92.2 | 4.3 | 3.0-6.5 | 6.1 | 4.0-15.3 | 2.9 | 2.1-4.3 | 8.2 | 6.0-12.7 | 41.1 ± 4.2 |
| CNS tumor† | 12 | 6.0 | 6 | 50.0 | 9 | 90.0 | 5.0 | 3.5-8.9 | 7.4 | 3.7-34.4 | 6.8 | 2.7-7.4 | 13.1 | 8.7-17.2 | 32.1 ± 15.0 |
| Carcinoma† | 19 | 9.5 | 7 | 36.8 | 15 | 83.3 | 4.7 | 3.0-8.7 | 6.6 | 3.3-38.5 | 11.8 | 6.1-16.1 | 16.2 | 10.7-23.4 | 77.4 ± 10.0 |
| Other† | 25 | 12.4 | 15 | 60.0 | 19 | 82.6 | 5.7 | 3.4-8.1 | 4.9 | 2.5-26.2 | 7.8 | 4.4-9.8 | 14.0 | 10.4-17.9 | 44.9 ± 11.3 |
Abbreviations: ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; SMN, second malignant neoplasm.
Nine patients were excluded because immunophenotype was not reported (n = 8) or was not specified as either BCP or T-cell ALL (n = 1).
Seventy-one acute myeloid leukemia, 38 myelodysplastic syndrome, three chronic myeloid leukemia, 23 non-Hodgkin lymphoma, 10 Hodgkin disease, 10 nonmeningioma CNS tumors, two meningioma, 10 nonthyroid carcinoma, nine thyroid carcinoma, seven soft tissue sarcoma, 12 bone tumors, one germ cell tumor, four Langerhans cell histiocytosis, one other tumor.